Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients (BRAVO)

4. mai 2015 oppdatert av: Mary McDermott, Northwestern University

The investigators hypothesize that among people with lower extremity peripheral artery disease (PAD), biomarker levels are higher during time periods immediately preceding an acute coronary event compared to time periods not immediately preceding an acute coronary event. Biomarkers the investigators will study are CRP, SAA, and D-dimer. Biomarkers will be measured at baseline and every two months during follow-up.

The primary aims of this study are as follows. Specific Aim #1. Among participants with PAD who experience an acute coronary event during follow-up, the investigators will determine whether biomarker levels measured immediately prior to the coronary event are higher than levels that do not immediately precede coronary events. Specific Aim #2, Part 1. The investigators will determine whether participants who experience a coronary event (cases) have higher biomarker levels at the visit immediately prior to the event than participants who have not experienced a coronary event (controls) at the time of the case event. Specific Aim #2, Part 2. The investigators will determine whether participants who experience a coronary event (cases) have a greater increase in biomarkers during the time period leading up to the event compared to participants who have not experienced a coronary event (controls).

To achieve these aims, the investigators will enroll up to 650 participants with PAD and follow them prospectively, measuring blood samples every two months, and ascertaining the presence of acute coronary events every two months.

Studieoversikt

Status

Fullført

Studietype

Observasjonsmessig

Registrering (Faktiske)

595

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • University of Chicago Medical Center
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern University Feinberg School of Medicine
      • Chicago, Illinois, Forente stater, 60612
        • Rush Medical Center
      • Chicago, Illinois, Forente stater, 60608
        • Mt. Sinai Medical Center
      • Chicago, Illinois, Forente stater, 60612
        • Jesse Brown Veterans Administration Medical Center
      • Chicago, Illinois, Forente stater, 60657
        • St. Joseph's Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories and vascular surgery, cardiology, general internal medicine, geriatric, and endocrinology clinics.

Beskrivelse

Inclusion Criteria:

  • Peripheral arterial disease defined as an ABI less than or equal to 0.90 in either leg

We will also include PAD patients with an ABI > 0.90 who meet any of the following criteria:

  • History of documented lower extremity revascularization. A written report from the medical record will be required as documentation
  • An angiogram demonstrating >50% stenosis in one or more lower extremity arteries. Again, a written report will be required to document this. Participants with an angiogram noting moderate or greater stenosis will also be considered eligible, when a specific amount of stenosis is not denoted
  • A report from the non-invasive vascular laboratory demonstrating a toe brachial pressure less than 0.60. Other criteria (i.e. PVR data) from the non-invasive vascular laboratory will not be considered sufficient for inclusion

Exclusion Criteria:

  • Treatment for cancer other than non-melanoma skin cancer during the previous 2 years. (However, persons treated for non-invasive breast cancer or prostate cancer during the previous year will be potentially eligible if their physician indicates that their life expectancy is > 24 months, since non-invasive breast and prostate cancer often have an excellent prognosis)
  • Unintentional weight loss of > 7.5 pounds in the last six months;
  • Mini-Mental Status Exam (MMSE) score < 23 out of 30 or other history of cognitive impairment
  • Communication difficulty due to language barriers
  • Refusal to have regular blood draws or inability to obtain a blood sample at baseline
  • Coronary or cerebrovascular event during the previous six months (these persons may become eligible at a later date)
  • History of inflammatory arthritis (rheumatoid arthritis, lupus erythematosis, or polymyalgia rheumatic, gout), however participants with gouty arthritis will be eligible if the last episode was more than three months ago
  • Residence more than 40 miles away from the medical center and unwillingness to travel to the medical center for every two month blood collection
  • Unable to return for follow up testing for > a consecutive six month period in the next two years
  • Heart transplant surgery
  • Major surgery (one that required general anesthesia) within the past 3 months These persons may become eligible at a later date

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
PAD Participants
PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
fatal and non-fatal coronary events
Tidsramme: Every two months for up to three and a half years
Our primary outcome is fatal and non-fatal coronary events. Non-fatal coronary events will be defined as acute myocardial infarction (MI), hospitalizations for unstable angina, and new ECG findings consistent with MI
Every two months for up to three and a half years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2009

Primær fullføring (Faktiske)

1. januar 2013

Studiet fullført (Faktiske)

1. januar 2013

Datoer for studieregistrering

Først innsendt

24. oktober 2014

Først innsendt som oppfylte QC-kriteriene

27. oktober 2014

Først lagt ut (Anslag)

28. oktober 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

6. mai 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. mai 2015

Sist bekreftet

1. mai 2015

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Perifer arteriell sykdom

3
Abonnere